Recombinant Rat KLRB1A/CD161a protein (rFc Tag)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Rat KLRB1A/CD161a protein (rFc Tag) (Eg1466)

Species

Rat

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg1466

---

Validation Data Gallery

• 

  Purity of Recombinant Rat KLRB1A was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Rat KLRB1A protein Arg64-Ser223 (Accession# P27471) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 362443
• Accession: P27471
• PredictedSize: 44.3 kDa
• SDS-PAGE: 50-65 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CD161, also known as KLRB1 or NKR-P1A, is a type II transmembrane C-type lectin-like receptor and is expressed on the cell membrane as disulfide-linked homodimer. It is expressed by the majority of NK cells and subsets of peripheral T cells, including both CD4+ and CD8+ T cells, and is expressed preferentially on adult T cells with a "memory" antigenic phenotype. Expression of CD161 correlates with the cytotoxic function of CD16+ NK cells, and ligation of CD161 with its ligand LLT1 inhibits NK cell cytotoxicity and cytokine secretion.

References:

1.Lanier LL, et al. (1994) J Immunol. 153(6):2417-28.
2.Fergusson JR, et al. (2011) Front Immunol. 2:36.
3.Kurioka A, et al. (2018) Front Immunol. 9:486.